Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 43

1.

Personalized Treatment of H3K27M-Mutant Pediatric Diffuse Gliomas Provides Improved Therapeutic Opportunities.

Gojo J, Pavelka Z, Zapletalova D, Schmook MT, Mayr L, Madlener S, Kyr M, Vejmelkova K, Smrcka M, Czech T, Dorfer C, Skotakova J, Azizi AA, Chocholous M, Reisinger D, Lastovicka D, Valik D, Haberler C, Peyrl A, Noskova H, Pál K, Jezova M, Veselska R, Kozakova S, Slaby O, Slavc I, Sterba J.

Front Oncol. 2020 Jan 10;9:1436. doi: 10.3389/fonc.2019.01436. eCollection 2019.

2.

Serial Xenotransplantation in NSG Mice Promotes a Hybrid Epithelial/Mesenchymal Gene Expression Signature and Stemness in Rhabdomyosarcoma Cells.

Skoda J, Neradil J, Staniczkova Zambo I, Nunukova A, Macsek P, Borankova K, Dobrotkova V, Nemec P, Sterba J, Veselska R.

Cancers (Basel). 2020 Jan 13;12(1). pii: E196. doi: 10.3390/cancers12010196.

3.

Comparative Analysis of Putative Prognostic and Predictive Markers in Neuroblastomas: High Expression of PBX1 Is Associated With a Poor Response to Induction Therapy.

Veselska R, Jezova M, Kyr M, Mazanek P, Chlapek P, Dobrotkova V, Sterba J.

Front Oncol. 2019 Nov 15;9:1221. doi: 10.3389/fonc.2019.01221. eCollection 2019.

4.

Phospho-Protein Arrays as Effective Tools for Screening Possible Targets for Kinase Inhibitors and Their Use in Precision Pediatric Oncology.

Neradil J, Kyr M, Polaskova K, Kren L, Macigova P, Skoda J, Sterba J, Veselska R.

Front Oncol. 2019 Sep 20;9:930. doi: 10.3389/fonc.2019.00930. eCollection 2019.

5.

Individualization of Treatment Improves the Survival of Children With High-Risk Solid Tumors: Comparative Patient Series Analysis in a Real-Life Scenario.

Kyr M, Polaskova K, Kuttnerova Z, Merta T, Neradil J, Berkovcova J, Horky O, Jezova M, Veselska R, Klement GL, Valik D, Sterba J.

Front Oncol. 2019 Jul 17;9:644. doi: 10.3389/fonc.2019.00644. eCollection 2019.

6.

Prediction of neuroblastoma cell response to treatment with natural or synthetic retinoids using selected protein biomarkers.

Dobrotkova V, Chlapek P, Jezova M, Adamkova K, Mazanek P, Sterba J, Veselska R.

PLoS One. 2019 Jun 12;14(6):e0218269. doi: 10.1371/journal.pone.0218269. eCollection 2019.

7.

New inhibitor of the TAp73 interaction with MDM2 and mutant p53 with promising antitumor activity against neuroblastoma.

Gomes S, Raimundo L, Soares J, Loureiro JB, Leão M, Ramos H, Monteiro MN, Lemos A, Moreira J, Pinto M, Chlapek P, Veselska R, Sousa E, Saraiva L.

Cancer Lett. 2019 Apr 1;446:90-102. doi: 10.1016/j.canlet.2019.01.014. Epub 2019 Jan 19.

PMID:
30664963
8.

Pharmacological targeting of mitochondria in cancer stem cells: An ancient organelle at the crossroad of novel anti-cancer therapies.

Skoda J, Borankova K, Jansson PJ, Huang ML, Veselska R, Richardson DR.

Pharmacol Res. 2019 Jan;139:298-313. doi: 10.1016/j.phrs.2018.11.020. Epub 2018 Nov 16. Review.

PMID:
30453033
9.

Traffic lights for retinoids in oncology: molecular markers of retinoid resistance and sensitivity and their use in the management of cancer differentiation therapy.

Dobrotkova V, Chlapek P, Mazanek P, Sterba J, Veselska R.

BMC Cancer. 2018 Nov 1;18(1):1059. doi: 10.1186/s12885-018-4966-5. Review.

10.

Effects of Sunitinib and Other Kinase Inhibitors on Cells Harboring a PDGFRB Mutation Associated with Infantile Myofibromatosis.

Sramek M, Neradil J, Macigova P, Mudry P, Polaskova K, Slaby O, Noskova H, Sterba J, Veselska R.

Int J Mol Sci. 2018 Sep 1;19(9). pii: E2599. doi: 10.3390/ijms19092599.

11.

Cancer stem cells in sarcomas: Getting to the stemness core.

Skoda J, Veselska R.

Biochim Biophys Acta Gen Subj. 2018 Oct;1862(10):2134-2139. doi: 10.1016/j.bbagen.2018.07.006. Epub 2018 Jul 9. Review.

PMID:
30003939
12.

Why Differentiation Therapy Sometimes Fails: Molecular Mechanisms of Resistance to Retinoids.

Chlapek P, Slavikova V, Mazanek P, Sterba J, Veselska R.

Int J Mol Sci. 2018 Jan 3;19(1). pii: E132. doi: 10.3390/ijms19010132. Review.

13.

Uniformity under in vitro conditions: Changes in the phenotype of cancer cell lines derived from different medulloblastoma subgroups.

Chlapek P, Zitterbart K, Kren L, Filipova L, Sterba J, Veselska R.

PLoS One. 2017 Feb 23;12(2):e0172552. doi: 10.1371/journal.pone.0172552. eCollection 2017.

14.

Case report: rapid and durable response to PDGFR targeted therapy in a child with refractory multiple infantile myofibromatosis and a heterozygous germline mutation of the PDGFRB gene.

Mudry P, Slaby O, Neradil J, Soukalova J, Melicharkova K, Rohleder O, Jezova M, Seehofnerova A, Michu E, Veselska R, Sterba J.

BMC Cancer. 2017 Feb 10;17(1):119. doi: 10.1186/s12885-017-3115-x.

15.

Much more than you expected: The non-DHFR-mediated effects of methotrexate.

Sramek M, Neradil J, Veselska R.

Biochim Biophys Acta Gen Subj. 2017 Mar;1861(3):499-503. doi: 10.1016/j.bbagen.2016.12.014. Epub 2016 Dec 16. Review.

PMID:
27993660
16.

Co-Expression of Cancer Stem Cell Markers Corresponds to a Pro-Tumorigenic Expression Profile in Pancreatic Adenocarcinoma.

Skoda J, Hermanova M, Loja T, Nemec P, Neradil J, Karasek P, Veselska R.

PLoS One. 2016 Jul 14;11(7):e0159255. doi: 10.1371/journal.pone.0159255. eCollection 2016.

17.

Expression of nestin, CD133 and ABCG2 in relation to the clinical outcome in pediatric sarcomas.

Zambo I, Hermanova M, Zapletalova D, Skoda J, Mudry P, Kyr M, Zitterbart K, Sterba J, Veselska R.

Cancer Biomark. 2016 Jun 7;17(1):107-16. doi: 10.3233/CBM-160623.

PMID:
27314299
18.

Non-DHFR-mediated effects of methotrexate in osteosarcoma cell lines: epigenetic alterations and enhanced cell differentiation.

Sramek M, Neradil J, Sterba J, Veselska R.

Cancer Cell Int. 2016 Feb 29;16:14. doi: 10.1186/s12935-016-0289-2. eCollection 2016.

19.

Cancer stem cell markers in pediatric sarcomas: Sox2 is associated with tumorigenicity in immunodeficient mice.

Skoda J, Nunukova A, Loja T, Zambo I, Neradil J, Mudry P, Zitterbart K, Hermanova M, Hampl A, Sterba J, Veselska R.

Tumour Biol. 2016 Jul;37(7):9535-48. doi: 10.1007/s13277-016-4837-0. Epub 2016 Jan 20.

PMID:
26790443
20.

Atypical nuclear localization of CD133 plasma membrane glycoprotein in rhabdomyosarcoma cell lines.

Nunukova A, Neradil J, Skoda J, Jaros J, Hampl A, Sterba J, Veselska R.

Int J Mol Med. 2015 Jul;36(1):65-72. doi: 10.3892/ijmm.2015.2210. Epub 2015 May 14.

Supplemental Content

Loading ...
Support Center